Tech Support


This line is for technical support.
For General Enquiries please click General Contact

HUB Organoids - In Vitro Services


HUB Organoids for Drug Development

In Vitro Screening with PDO and PDXO

HUB Tumor Organoids with representative colorectal exampleCrownBio has entered into an exclusive partnership with Hubrecht Organoid Technology (HUB) to provide preclinical drug development and validation services using HUB organoid technology and the HUB tumor organoid biobank.

HUB Biobank Organoids

CrownBio’s HUB Organoid Services are expected to be available by late 2019! This highly translational in vitro screening platform includes the development of patient-derived organoids (PDO), as well as PDX-derived organoids (PDXO) from CrownBio’s extensive patient-derived xenograft (PDX) collection.

HUB Organoid Models Currently In Development

HUB’s adult stem cell-derived organoids, originally developed in the Clevers Lab are generated using highly standardized, proprietary culture methods. The organoids faithfully recapitulate tumors in patients and are extensively characterized by pathology, genomics, and sensitivity to known and experimental drugs.

Colorectal Pancreatic Lung Breast

Help Us Build The Optimum Organoids Service Portfolio

Your input will help us to build the most useful preclinical platform, and prioritize model development. We greatly appreciate your participation in our quick 2 minute survey.

Take Our 2 Minute Survey

Join the Organoids Mailing List

To receive the most up to date information on CrownBio's Organoid Service development, simply complete the the form to the right. You'll receive the latest information, news, and content about organoids and HUB organoids.

What Are Organoids

The term organoids is currently used to signify 3D cell-based models derived from adult, embryonic, or induced pluripotent stem cells which are maintained in vitro to give rise to mini-organs.

Organoids represent the only in vitro technology to faithfully recapitulate original tissue physiology, providing a fast and cost-effective model for applications such as drug development and tissue engineering.

HUB tumor organoids have emerged as a robust preclinical model to predict clinical outcomes in patients, providing enhanced oncology model options for drug development programs. Organoids are also used in many applications and are in widespread use.

Receive the latest Organoid News

Complete the form below to get the latest updates on our service development